COMPARE · Data as of August 27, 2026
ADMA vs NKTR
Verdict: Side-by-side breakdown using the Bull Rankings model. ADMA scored 81.7, NKTR scored 25.8 — ADMA leads.
Compare another set
ADMA
ADMA Biologics, Inc.
81.7
$9.71 · $2.2B
fundamentals as of
Score gap
55.9
ADMA leads
NKTR
Nektar Therapeutics
25.8
$74.55 · $2.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthADMA+8.0%
- Strongest balance sheetNKTR0.15
- Highest qualityADMA84 / 100
- Largest discount to fair valueADMA-33%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ADMA
stronger →← stronger
NKTR
84
Qualityreturns · margins · balance sheet
18
77
Growthrevenue & earnings expansion
14
84
Valuevaluation vs sector peers
69
ADMA is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ADMA
NKTR
$116mC
FCF
-$234mF
+8.0%B
Rev
-43.9%F
1.11C
D/E
0.15B+
13.9xA-
P/E
—
0.58A-
PEG
0.31A
—
P/S
46.6xD
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADMA
NKTR
33% below
Price vs fair valuelower is cheaper
—
~4%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+15%
1-yr DCF upside
—
+49%
5-yr DCF upside
—
+120%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADMA
Why this score
- Buying back stock
- Durable high returns
- Earnings outpace cash
NKTR
Why this score
- Diluting shareholders
The companies
ADMAADMA Biologics, Inc.
Why now
Biotechnology · market cap $2.2b. Down 53% from 52-week high of $20.46 — deep drawdown territory. PEG 0.58 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $17.00 (implying +75% upside).
Moat
Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 53% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
NKTRNektar Therapeutics
Why now
Biotechnology · market cap $2.5b. Down 32% from 52-week high of $109.00 — deep drawdown territory. Revenue -44% — in contraction; any catalyst that reverses this triggers re-rating. PEG 0.31 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $144.40 (implying +94% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$234m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -44% — the operational turn is not yet visible in the top line. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ADMA and NKTR diverge
On the headline score the gap is 55.9 points in favor of ADMA. The widest single difference is Quality, where ADMA leads by 66.1 points.
- QualityADMA 84.1 · NKTR 18.0ADMA +66.1
- GrowthADMA 76.9 · NKTR 13.8ADMA +63.1
- ValueADMA 84.3 · NKTR 69.0ADMA +15.3
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.